FTC Seeks Generic Drug Delay Limits

The Federal Trade Commission wants to limit the ability of drug companies to delay the marketing of generic competitors and to require the firms to disclose agreements covering the sales of generic drugs.

``The commission's recommendations today are designed to accomplish two goals: to facilitate generic entry and to maintain appropriate incentives for the development of new drug products,'' said FTC chairman Timothy J. Muris.

Hopefully, this recommendation will allow faster entry of generics into the market.